Related Experiment Video
Updated: Mar 26, 2026

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Management of infantile spasms
1Division of Child Neurology, University of Utah School of Medicine, Salt Lake City, USA.
West syndrome, or infantile spasms, is a severe infant epilepsy. Early diagnosis via MRI and prompt treatment with ACTH, prednisolone, or vigabatrin improve outcomes, though neurodevelopmental delays are common.
Area of Science:
- Neurology
- Pediatrics
- Epileptology
Background:
- West syndrome, also known as infantile spasms, is a severe epileptic encephalopathy in infants.
- It has diverse underlying causes, necessitating a thorough diagnostic approach.
- Early diagnosis and treatment are crucial for managing this condition.
Purpose of the Study:
- To review the diagnostic approaches for West syndrome.
- To outline current treatment strategies and evidence.
- To discuss the prognostic factors influencing neurodevelopmental outcomes.
Main Methods:
- Review of current literature on West syndrome diagnosis and treatment.
- Emphasis on the role of Magnetic Resonance Imaging (MRI) in etiological diagnosis.
- Analysis of evidence for first-line therapies like ACTH, prednisolone, and vigabatrin.
Main Results:
- MRI is the most effective initial imaging study for identifying the cause of infantile spasms.
- Adrenocorticotropic hormone (ACTH), prednisolone, and vigabatrin are recognized first-line treatments.
- The ketogenic diet and other anti-epileptic drugs may also be beneficial.
Conclusions:
- Accurate diagnosis guides treatment selection for infantile spasms.
- While prognosis is often poor with neurodevelopmental delays, early intervention in specific cases can lead to better outcomes.
- Further research is needed to establish optimal treatment regimens.
Related Concept Videos
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Skeletal Muscle Relaxants: Therapeutic Uses
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

